ARS Pharmaceuticals Inc (NASDAQ: SPRY) has a higher price-to-earnings ratio of 187.48x compared to its average ratio, The 36-month beta value for SPRY is at 0.71. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SPRY is 56.04M, and currently, shorts hold a 30.60% of that float. The average trading volume for SPRY on April 24, 2025 was 1.70M shares.
SPRY) stock’s latest price update
ARS Pharmaceuticals Inc (NASDAQ: SPRY)’s stock price has dropped by -4.13 in relation to previous closing price of 15.00. Nevertheless, the company has seen a loss of -4.07% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-20 that ARS Pharmaceuticals, Inc.’s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy’s competitive edge lies in its innovative intranasal delivery, targeting a $3 billion initial addressable market in the U.S. with potential growth prospects. Despite neffy’s potential, risks include competition, pricing pressures, and single-asset dependency, leading to a “Hold” recommendation due to commercial uncertainties.
SPRY’s Market Performance
ARS Pharmaceuticals Inc (SPRY) has experienced a -4.07% fall in stock performance for the past week, with a 11.56% rise in the past month, and a 6.13% rise in the past quarter. The volatility ratio for the week is 6.08%, and the volatility levels for the past 30 days are at 7.55% for SPRY. The simple moving average for the past 20 days is 6.21% for SPRY’s stock, with a 12.15% simple moving average for the past 200 days.
Analysts’ Opinion of SPRY
Many brokerage firms have already submitted their reports for SPRY stocks, with Scotiabank repeating the rating for SPRY by listing it as a “Sector Outperform.” The predicted price for SPRY in the upcoming period, according to Scotiabank is $30 based on the research report published on March 07, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see SPRY reach a price target of $40. The rating they have provided for SPRY stocks is “Outperform” according to the report published on February 10th, 2025.
SPRY Trading at 16.72% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.31% of loss for the given period.
Volatility was left at 7.55%, however, over the last 30 days, the volatility rate increased by 6.08%, as shares surge +9.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.49% upper at present.
During the last 5 trading sessions, SPRY fell by -4.07%, which changed the moving average for the period of 200-days by +58.02% in comparison to the 20-day moving average, which settled at $13.54. In addition, ARS Pharmaceuticals Inc saw 36.30% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Shawver Laura, who sale 50,002 shares at the price of $12.30 back on Apr 07 ’25. After this action, Shawver Laura now owns 210,346 shares of ARS Pharmaceuticals Inc, valued at $615,075 using the latest closing price.
Shawver Laura, the Director of ARS Pharmaceuticals Inc, proposed sale 50,002 shares at $12.30 during a trade that took place back on Apr 07 ’25, which means that Shawver Laura is holding shares at $615,051 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.99 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at 0.09. The total capital return value is set at -0.01. Equity return is now at value 3.28, with 2.74 for asset returns.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 322.57.
Currently, EBITDA for the company is -3.08 million with net debt to EBITDA at 16.63. When we switch over and look at the enterprise to sales, we see a ratio of 15.26. The receivables turnover for the company is 9.73for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.26.
Conclusion
In conclusion, ARS Pharmaceuticals Inc (SPRY) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
